Savara (NASDAQ: SVRA) reported Q1 EPS of ($0.88), $0.52 worse than the analyst estimate of ($0.36).

• AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019
• First patient enrolled in Molgradex IMPALA-X safety extension study

For earnings history and earnings-related data on Savara (SVRA) click here.